Greenvale plots course on Australia’s big uranium roadmap
Australia could end up being home to half of the world’s uranium resources – and Greenvale Energy wants to get in on the action.
Stockhead
CR3 to emulate Latin Resources success
Executive director Anthony Greenaway is looking to bring the same core principals applied during his tenure with Latin Resources to Core Energy Minerals.
CSL weighs on health sector
Morgans analyst Scott Power said its been a big week for the ASX healthcare sector with half year results and Chemist Warehouse hitting the bourse through its merger with Sigma Healthcare.
QMines loads up for copper drilling
ASX junior QMines is ready to reap the rewards of a rising copper price as it restocks to explore its Mt Chalmers and Develin Creek projects.
More Stories
Optiscan kicks off GI study in Germany
Optiscan completes first gastrointestinal (GI) flexible prototype to collect images from the GI tract and activates GI study at major German university.
OZM’s high-grade gold hits excites punters
OzAurum’s high-grade drill hits at the Mulgabbie North project have identified a new zone that outlines its potential to host significant mineralisation.
Caprice targets maiden gold resource
Caprice has recommenced drilling at its promising Island gold project, which hosts historic workings just 12km from Ramelius’ Cue mine.
OZM hits high-grade gold at Mulgabbie North
Drill hits of up to 4m at 14.17g/t gold have led to OzAurum identifying a new high-grade target at its Mulgabbie North gold project.
Cash backs Indiana’s golden opportunity
Indiana Resources is a rare junior with massive cash backing, but its South Australian gold prospects could be the real value driver.
Paradigm eyes $110m raise with loyalty offer
Paradigm Biopharmaceuticals has launched loyalty options and piggyback options offers which could potentially raise more than $110 million.
How major commodities fared in 2024
Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a tumultuous 2024.
Shares dive on Trump’s tariffs
The ASX has crashed today on Trump’s tariffs. Meanwhile oil has risen, crypto has absolutely face-planted and Novonix is up on an anti-China dumping win.
PAR picks Advanced Clinical for key trial
Paradigm Biopharmaceuticals has selected Advanced Clinical as the preferred clinical research organisation for the phase III trial for PARA_OA_012.
AAR moves to acquire MXR
Astral Resources’ takeover offer values Maximus Resources at ~$31m and will provide more flexible future development of existing gold resources.
Original URL: https://www.themercury.com.au/business/stockhead/page/26